Endocrine therapies, such as tamoxifen and aromatase inhibitors (AIs), are widely used in the clinic for treating hormone-sensitive early-stage breast cancer. These therapies are proven to reduce recurrence and death from breast cancer. However, not every patient will benefit from taking tamoxifen/AIs. There are substantial side effects associated with tamoxifen and AIs and as a result, patients' adherences to endocrine therapy are low. This highlights the crucial need for an early response marker for measuring the clinical efficacy (e.g., reduce breast cancer recurrence) of tamoxifen/AIs so that only women who are likely to benefit from the treatment will be subjected to the associated side effects. Several studies have shown mammographic breast density is associated with tamoxifen/AI use. The goal of this study is to perform a clinical evaluation of automated breast density assessment for translational use to monitor the effectiveness of adjuvant tamoxifen/AI therapy in predicting breast cancer recurrence. Our retrospective study is innovative in terms of using standard of care digital mammogram images to evaluate automated breast density assessment for translational/clinical use. The results of this study will provide to the clinic a clinical imaging-based early response biomarker that is reproducible, low-cost, and based on standard of care breast images, allowing personalized evaluation on the effects of adjuvant endocrine therapy.

Public Health Relevance

): We propose to conduct a clinical evaluation of automated assessment of breast dense tissue in digital mammograms as a response biomarker for adjuvant tamoxifen or aromatase inhibitor (AI) use in breast cancer patients. The results of this study will provide to the clinic a clinical imaging-based early response biomarker that is reproducible, low-cost, and based on standard of care breast images. Clinical validation of the biomarkers will help identify individual woman who will, or will not, benefit from taking tamoxifen/AIs. This should encourage drug adherence in those who will benefit, while allowing those who will not benefit to consider alternative therapies and avoid the substantial side effects of tamoxifen/AIs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA193603-03S1
Application #
9443118
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Zhang, Huiming
Project Start
2015-07-01
Project End
2019-06-30
Budget Start
2018-01-04
Budget End
2018-06-30
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Mohamed, Aly A; Berg, Wendie A; Peng, Hong et al. (2018) A deep learning method for classifying mammographic breast density categories. Med Phys 45:314-321
Ma, Wenjuan; Zhao, Yumei; Ji, Yu et al. (2018) Breast Cancer Molecular Subtype Prediction by Mammographic Radiomic Features. Acad Radiol :
Mohamed, Aly A; Luo, Yahong; Peng, Hong et al. (2018) Understanding Clinical Mammographic Breast Density Assessment: a Deep Learning Perspective. J Digit Imaging 31:387-392
Aboutalib, Sarah S; Mohamed, Aly A; Berg, Wendie A et al. (2018) Deep Learning to Distinguish Recalled but Benign Mammography Images in Breast Cancer Screening. Clin Cancer Res 24:5902-5909
Wu, Shandong; Zuley, Margarita L; Berg, Wendie A et al. (2017) DCE-MRI Background Parenchymal Enhancement Quantified from an Early versus Delayed Post-contrast Sequence: Association with Breast Cancer Presence. Sci Rep 7:2115
Wu, Shandong; Berg, Wendie A; Zuley, Margarita L et al. (2016) Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer. Breast Cancer Res 18:76